Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On May2, 2017, Intersect ENT, Inc. (the Company) issued a press
release announcing its financial results for the first quarter
ended March31, 2017. A copy of the press release is furnished as
an Exhibit 99.1 to this Current Report and is incorporated herein
by reference.
The information in this Form 8-K and the Exhibit attached hereto
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 |
Press release entitled Intersect ENT Reports First Quarter 2017 Results dated May2, 2017. |
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant. Intersect ENT, Inc. (NASDAQ:XENT) Recent Trading Information
Intersect ENT, Inc. (NASDAQ:XENT) closed its last trading session up +0.10 at 20.05 with 317,777 shares trading hands.